MX2019007870A - Inhibidores de poli-adp ribosa polimerasa (parp). - Google Patents
Inhibidores de poli-adp ribosa polimerasa (parp).Info
- Publication number
- MX2019007870A MX2019007870A MX2019007870A MX2019007870A MX2019007870A MX 2019007870 A MX2019007870 A MX 2019007870A MX 2019007870 A MX2019007870 A MX 2019007870A MX 2019007870 A MX2019007870 A MX 2019007870A MX 2019007870 A MX2019007870 A MX 2019007870A
- Authority
- MX
- Mexico
- Prior art keywords
- parp
- poly
- inhibitors
- ribose polymerase
- adp ribose
- Prior art date
Links
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 title abstract 3
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 title abstract 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invencion se relaciona con una composicion farmaceutica que comprende un vehiculo aceptable farmaceuticamente o un diluyente y un compuesto representado por la siguiente formula estructural : (ver formula) la presente invencion tambien se relaciona con un metodo para tratar un sujeto con una enfermedad que puede mejorarse mediante la inhibicion de la poli(ADP-ribosa)polimerasa (PARP); en la memoria descriptiva se proveen las definiciones de las variables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662440581P | 2016-12-30 | 2016-12-30 | |
| PCT/US2017/068636 WO2018125961A1 (en) | 2016-12-30 | 2017-12-28 | Poly-adp ribose polymerase (parp) inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019007870A true MX2019007870A (es) | 2019-08-16 |
| MX393606B MX393606B (es) | 2025-03-19 |
Family
ID=61007849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019007870A MX393606B (es) | 2016-12-30 | 2017-12-28 | Inhibidores de poli-adp ribosa polimerasa (parp) |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11034670B2 (es) |
| EP (1) | EP3562822B1 (es) |
| JP (1) | JP7141399B2 (es) |
| KR (1) | KR102606799B1 (es) |
| CN (1) | CN110167926B (es) |
| AR (1) | AR110706A1 (es) |
| AU (1) | AU2017388376B2 (es) |
| CA (1) | CA3047137A1 (es) |
| CO (1) | CO2019007906A2 (es) |
| CY (1) | CY1124565T1 (es) |
| DK (1) | DK3562822T3 (es) |
| EA (1) | EA201991412A1 (es) |
| ES (1) | ES2875841T3 (es) |
| HR (1) | HRP20210887T1 (es) |
| HU (1) | HUE054382T2 (es) |
| IL (1) | IL267676B (es) |
| JO (1) | JOP20190115B1 (es) |
| LT (1) | LT3562822T (es) |
| MA (1) | MA47165B1 (es) |
| MD (1) | MD3562822T2 (es) |
| MX (1) | MX393606B (es) |
| MY (1) | MY199045A (es) |
| PH (1) | PH12019501529A1 (es) |
| PL (1) | PL3562822T3 (es) |
| PT (1) | PT3562822T (es) |
| RS (1) | RS61895B1 (es) |
| SA (1) | SA519401894B1 (es) |
| SI (1) | SI3562822T1 (es) |
| SM (1) | SMT202100321T1 (es) |
| TW (1) | TWI773718B (es) |
| UA (1) | UA124777C2 (es) |
| WO (1) | WO2018125961A1 (es) |
| ZA (2) | ZA201904004B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102667385B1 (ko) * | 2015-10-07 | 2024-05-21 | 미토브리지, 인크. | Ppar 효능제, 화합물, 제약 조성물, 및 그의 사용 방법 |
| MA47165B1 (fr) * | 2016-12-30 | 2021-06-30 | Mitobridge Inc | Inhibiteurs de la poly-adp-ribose polymérase (parp) |
| US12459899B2 (en) | 2019-10-30 | 2025-11-04 | DIGMBIO, Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| MX2023012361A (es) * | 2021-04-22 | 2023-10-31 | Wigen Biomedicine Tech Shanghai Co Ltd | Inhibidor de parp que contiene estructura de piperazina, metodo de preparacion del mismo y uso farmaceutico del mismo. |
| KR20240057402A (ko) * | 2021-07-23 | 2024-05-02 | 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 | 그람 음성 박테리아 유출 펌프 억제제 |
| CN113603630B (zh) * | 2021-08-10 | 2023-06-27 | 苏州小栗医药科技有限公司 | 一种4-苯基哌啶盐酸盐的合成方法 |
| WO2024061768A1 (en) | 2022-09-19 | 2024-03-28 | Basf Se | Azole pesticidal compounds |
| JPWO2024101336A1 (es) | 2022-11-07 | 2024-05-16 | ||
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN120917007A (zh) * | 2023-05-19 | 2025-11-07 | 上海海和药物研究开发股份有限公司 | 一种芳基脲类parp1抑制剂、其制备方法及用途 |
| CN117024357A (zh) * | 2023-07-03 | 2023-11-10 | 潍坊医学院 | 一种针对brca突变的选择性抑制剂及其用途 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| CN117510404A (zh) * | 2023-11-29 | 2024-02-06 | 山西永津集团有限公司 | 一种4-氨基烟酸的制备方法 |
| WO2025111705A1 (en) * | 2023-11-30 | 2025-06-05 | Waverley Pharma Inc. | Quinazolinone derivatives as poly (adp ribose) polymerase 1 (parp-1) inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| CN118084678B (zh) * | 2024-03-01 | 2024-09-06 | 长沙唯楚医药科技有限公司 | 一种2-溴-6-氟苯胺的制备方法 |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001070737A2 (en) | 2000-03-20 | 2001-09-27 | Sepracor, Inc. | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof |
| WO2001072306A1 (de) | 2000-03-27 | 2001-10-04 | Basf Aktiengesellschaft | Verwendung von dopamin-d3-rezeptor-liganden zur behandlung von erkrankungen des zentralen nervensystems |
| AUPR201600A0 (en) | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| CA2557541C (en) | 2004-02-26 | 2014-12-16 | Aska Pharmaceutical Co., Ltd. | Pyrimidine derivatives |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| JP4836946B2 (ja) * | 2004-06-30 | 2011-12-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｐａｒｐ阻害剤としての置換２−アルキルキナゾリノン誘導体 |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| MX2008000745A (es) | 2005-07-15 | 2008-03-14 | Schering Corp | Derivados de quinazolina utiles en el tratamiento del cancer. |
| JPWO2007099828A1 (ja) | 2006-02-23 | 2009-07-16 | 塩野義製薬株式会社 | 環式基で置換された含窒素複素環誘導体 |
| WO2007110868A2 (en) | 2006-03-28 | 2007-10-04 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
| US9353067B2 (en) | 2011-04-10 | 2016-05-31 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| CN102838600A (zh) | 2011-06-24 | 2012-12-26 | 山东亨利医药科技有限责任公司 | 苯基喹唑啉类PI3Kδ抑制剂 |
| US9505749B2 (en) * | 2012-08-29 | 2016-11-29 | Amgen Inc. | Quinazolinone compounds and derivatives thereof |
| US9901577B2 (en) | 2013-07-31 | 2018-02-27 | Merck Patent Gmbh | Oxoquinazolinyl-butanamide derivatives |
| BR112016025396A2 (pt) | 2014-05-07 | 2017-08-15 | Merck Patent Gmbh | derivados de heterociclil-butanamida |
| CN105924434A (zh) * | 2015-02-28 | 2016-09-07 | 广东东阳光药业有限公司 | 取代的氨基嘧啶类化合物及其使用方法和用途 |
| US11186564B2 (en) | 2016-08-04 | 2021-11-30 | Sunovion Pharmaceuticals Inc. | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders |
| MA47165B1 (fr) * | 2016-12-30 | 2021-06-30 | Mitobridge Inc | Inhibiteurs de la poly-adp-ribose polymérase (parp) |
-
2017
- 2017-12-28 MA MA47165A patent/MA47165B1/fr unknown
- 2017-12-28 HR HRP20210887TT patent/HRP20210887T1/hr unknown
- 2017-12-28 SI SI201730772T patent/SI3562822T1/sl unknown
- 2017-12-28 RS RS20210653A patent/RS61895B1/sr unknown
- 2017-12-28 PL PL17832694T patent/PL3562822T3/pl unknown
- 2017-12-28 LT LTEP17832694.8T patent/LT3562822T/lt unknown
- 2017-12-28 EA EA201991412A patent/EA201991412A1/ru unknown
- 2017-12-28 US US16/473,127 patent/US11034670B2/en active Active
- 2017-12-28 CA CA3047137A patent/CA3047137A1/en active Pending
- 2017-12-28 HU HUE17832694A patent/HUE054382T2/hu unknown
- 2017-12-28 AU AU2017388376A patent/AU2017388376B2/en active Active
- 2017-12-28 KR KR1020197021891A patent/KR102606799B1/ko active Active
- 2017-12-28 EP EP17832694.8A patent/EP3562822B1/en active Active
- 2017-12-28 PT PT178326948T patent/PT3562822T/pt unknown
- 2017-12-28 DK DK17832694.8T patent/DK3562822T3/da active
- 2017-12-28 SM SM20210321T patent/SMT202100321T1/it unknown
- 2017-12-28 MY MYPI2019003419A patent/MY199045A/en unknown
- 2017-12-28 WO PCT/US2017/068636 patent/WO2018125961A1/en not_active Ceased
- 2017-12-28 JP JP2019535356A patent/JP7141399B2/ja active Active
- 2017-12-28 JO JOP/2019/0115A patent/JOP20190115B1/ar active
- 2017-12-28 MD MDE20191268T patent/MD3562822T2/ro unknown
- 2017-12-28 ES ES17832694T patent/ES2875841T3/es active Active
- 2017-12-28 MX MX2019007870A patent/MX393606B/es unknown
- 2017-12-28 CN CN201780082024.8A patent/CN110167926B/zh active Active
- 2017-12-28 UA UAA201908940A patent/UA124777C2/uk unknown
- 2017-12-29 TW TW106146555A patent/TWI773718B/zh active
- 2017-12-29 AR ARP170103718A patent/AR110706A1/es active IP Right Grant
-
2019
- 2019-05-29 SA SA519401894A patent/SA519401894B1/ar unknown
- 2019-06-20 ZA ZA2019/04004A patent/ZA201904004B/en unknown
- 2019-06-26 IL IL267676A patent/IL267676B/en unknown
- 2019-06-28 PH PH12019501529A patent/PH12019501529A1/en unknown
- 2019-07-23 CO CONC2019/0007906A patent/CO2019007906A2/es unknown
-
2020
- 2020-06-03 ZA ZA2020/03310A patent/ZA202003310B/en unknown
-
2021
- 2021-06-08 CY CY20211100500T patent/CY1124565T1/el unknown
- 2021-06-09 US US17/342,873 patent/US11993585B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019007870A (es) | Inhibidores de poli-adp ribosa polimerasa (parp). | |
| CO2018013293A2 (es) | Derivados de pirazolopirimidina como inhibidor de quinasa | |
| MX2019007471A (es) | Composiciones y métodos para inhibir la actividad de la arginasa. | |
| MX2016009337A (es) | Derivados de azepano y metodos para tratar infecciones por hepatitis b. | |
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| MX2020004932A (es) | Compuestos utiles para inhibir a cdk7. | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| CL2015002530A1 (es) | Inhibidores de cdc7 | |
| CL2020001754A1 (es) | Derivado de amino-fluoropiperidina como inhibidor de quinasa. | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| ECSP17029203A (es) | Inhibidor de cinasa aurora a | |
| MX2019005402A (es) | Terapias de combinacion del inhibidor de arginasa. | |
| ECSP20035588A (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| CL2017001545A1 (es) | Formulaciones de 2-(terc-butilamino)-4-((1r,3r,4r)-3-hidroxi-4-metilciclohexilamino)-pirimidina-5-carboxamida | |
| GT201700099A (es) | 2- amino-6-(difluorometil)-5,5-difluoro-6-fenil-3, 4, 5, 6-tetrahidropiridinas como inhibidores de bace1 | |
| CL2019003258A1 (es) | Composiciones y compuestos terapéuticos y métodos para utilizarlos. | |
| MX2017010429A (es) | Acido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilami no)-2-hidroximetil-2-metilpentanoico. | |
| MX2015013151A (es) | Métodos de tratamiento de disquinesia y trastornos relacionados. | |
| MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| CO2019007836A2 (es) | Derivados de pirrolotriazina como inhibidor de cinasas | |
| AR105400A1 (es) | Inhibidores de jak1 | |
| AR102030A1 (es) | Métodos para tratar enfermedades del hígado |